Cargando…

Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK

BACKGROUND: Chronic migraine affects 2% of the population. It results in substantial disability and reduced quality of life. Medications used for prophylaxis in episodic migraine may also work in chronic migraine. The efficacy and safety of OnabotulinumtoxinA (BOTOX) in adults with chronic migraine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalil, Modar, Zafar, Hassan W, Quarshie, Victoria, Ahmed, Fayyaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166400/ https://www.ncbi.nlm.nih.gov/pubmed/25178393 http://dx.doi.org/10.1186/1129-2377-15-54

Ejemplares similares

EHMTI-0102. Prospective analysis of the use of onabotulinumtoxina (botox®) In the treatment of chronic migraine; real-life data in 299 patients from hull, UK
por: Khalil, M, et al.
Publicado: (2014)

Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
por: Ahmed, Fayyaz, et al.
Publicado: (2015)

OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients
por: Wong, Ho-Tin, et al.
Publicado: (2020)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review
por: Shaterian, Negar, et al.
Publicado: (2022)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Early development history of Botox (onabotulinumtoxinA)
por: Scott, Alan B., et al.
Publicado: (2023)

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)
por: Brin, Mitchell F., et al.
Publicado: (2023)

Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks
por: Oterino, A., et al.
Publicado: (2011)

Hull prospective analysis of Botulinum Toxin type A (Botox) use in the treatment of chronic migraine
por: Ahmed, F, et al.
Publicado: (2013)

Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Lowe, Nicholas, et al.
Publicado: (2023)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2020)

OnabotulinumtoxinA (Botox) in the Treatment of Crow’s Feet Lines in Japanese Subjects
por: Harii, Kiyonori, et al.
Publicado: (2017)

Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Jean, et al.
Publicado: (2023)

Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Scott, Alan B., et al.
Publicado: (2023)

Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Esquenazi, Alberto, et al.
Publicado: (2023)

Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Jankovic, Joseph, et al.
Publicado: (2023)

Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data
por: Lanteri-Minet, Michel, et al.
Publicado: (2022)

An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
por: Ahmed, Fayyaz, et al.
Publicado: (2019)

Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP)
por: Pallapothu, Manoj R, et al.
Publicado: (2023)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
por: Shabir, Habiba, et al.
Publicado: (2021)

Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Alastair, et al.
Publicado: (2023)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective
por: Hamid, Rizwan, et al.
Publicado: (2014)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

EHMTI-0090. Botox in the prevention of chronic migraine; comparing NICE criteria versus hull criteria for evaluating responder rate
por: Zafar, H, et al.
Publicado: (2014)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
por: Parrales Bravo, Franklin, et al.
Publicado: (2019)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
por: Zandieh, Ali, et al.
Publicado: (2022)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Gormley, Mark, et al.
Publicado: (2023)

Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age
por: Papetti, Laura, et al.
Publicado: (2023)

Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study
por: Rodríguez-Montolio, Joana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h7i5kh66e2fa5g4a9rqdd7nq1n